Bristol Myers Squibb trials: what clinicians said in public
HCP commentary reports on 4 clinical trials sponsored by Bristol Myers Squibb: EXCALIBER-RRMM, IZABRIGHT-Bladder01, IZABRIGHT-Lung01 and ROSETTA CRC-203. Each covers what clinicians said in public about one trial, on podcasts, videos and posts, every statement linked to its source. Below them, 82 more trials with public commentary and no report yet.
Listed by lead sponsor as registered on ClinicalTrials.gov (Bristol-Myers Squibb; Celgene; Mirati Therapeutics Inc.; Juno Therapeutics, a Subsidiary of Celgene; Juno Therapeutics, Inc., a Bristol-Myers Squibb Company; RayzeBio, Inc.; Turning Point Therapeutics, Inc.). A trial led by a partner or a research group is on that sponsor's page. Only trials with public clinician commentary found are listed, not every trial the sponsor runs.
| Trial | Indication | Phase | Statements | Sources | Size | Checked | Preview |
|---|---|---|---|---|---|---|---|
| IZABRIGHT-Bladder01 NCT07106762 · Bristol-Myers Squibb | metastatic urothelial cancer with progression after immunotherapy | Phase 2/Phase 3 | 16 | 8 | Focused | Nov 19, 2026 | Preview |
| EXCALIBER-RRMM NCT04975997 · Celgene | relapsed or refractory multiple myeloma | Phase 3 | 522 | 105 | Deep | Nov 17, 2026 | Preview |
| ROSETTA CRC-203 NCT07221357 · Bristol-Myers Squibb | previously untreated, unresectable or metastatic colorectal cancer | Phase 2/Phase 3 | 7 | 5 | Focused | Nov 16, 2026 | Preview |
| IZABRIGHT-Lung01 NCT07100080 · Bristol-Myers Squibb | EGFR-mutated non-small cell lung cancer after TKI failure | Phase 2/Phase 3 | 32 | 13 | Focused | Oct 29, 2026 | Preview |
| No report yetTrials with public commentary we haven't built a report for. Size is an estimate of the verified statements the commentary we've indexed so far will yield; final coverage is set when we build the report, within 24 hours of your confirmed order. You never pay more than quoted: a report delivered at a smaller size costs that size's price. Some can also be requested as a free preview. | |||||||
| CheckMate 214 NCT02231749 · Bristol-Myers Squibb DeepView → | previously untreated advanced or metastatic renal cell carcinoma | Phase 3 | Deep | View | |||
| CheckMate 274 NCT02632409 · Bristol-Myers Squibb DeepView → | high-risk invasive urothelial carcinoma | Phase 3 | Deep | View | |||
| CheckMate 9ER NCT03141177 · Bristol-Myers Squibb DeepView → | previously untreated advanced or metastatic renal cell carcinoma | Phase 3 | Deep | View | |||
| CheckMate 77T NCT04025879 · Bristol-Myers Squibb DeepView → | resectable stage II–IIIB non-small cell lung cancer | Phase 3 | Deep | View | |||
| CheckMate 227 NCT02477826 · Bristol-Myers Squibb DeepView → | first-line stage IV or recurrent NSCLC | Phase 3 | Deep | View | |||
| CheckMate 577 NCT02743494 · Bristol-Myers Squibb DeepView → | resected esophageal or gastroesophageal junction cancer | Phase 3 | Deep | View | |||
| KarMMa-3 NCT03651128 · Celgene DeepView → | triple-class-exposed relapsed and refractory multiple myeloma | Phase 3 | Deep | View | |||
| KRYSTAL-12 NCT04685135 · Mirati Therapeutics Inc. DeepView → | previously treated KRAS G12C-mutated advanced non-small-cell lung cancer | Phase 3 | Deep | View | |||
| KRYSTAL-1 NCT03785249 · Mirati Therapeutics Inc. DeepView → | KRAS G12C-mutated advanced solid tumors | Phase 1/Phase 2 | Deep | View | |||
| ENERGIZE NCT03661320 · Bristol-Myers Squibb DeepView → | muscle-invasive bladder cancer | Phase 3 | Deep | View | |||
| CheckMate 914 NCT03138512 · Bristol-Myers Squibb DeepView → | high-risk resected localized clear cell renal cell carcinoma | Phase 3 | Deep | View | |||
| KarMMa NCT03361748 · Celgene DeepView → | relapsed and refractory multiple myeloma | Phase 2 | Deep | View | |||
| CheckMate 067 NCT01844505 · Bristol-Myers Squibb DeepView → | previously untreated unresectable or metastatic melanoma | Phase 3 | Deep | View | |||
| CheckMate 9DW NCT04039607 · Bristol-Myers Squibb DeepView → | first-line unresectable hepatocellular carcinoma | Phase 3 | Deep | View | |||
| SUCCESSOR-2 NCT05552976 · Bristol-Myers Squibb DeepView → | relapsed or refractory multiple myeloma | Phase 3 | Deep | View | |||
| TRIDENT-1 NCT03093116 · Turning Point Therapeutics, Inc. DeepView → | ALK-, ROS1-, or NTRK-rearranged advanced solid tumors | Phase 1/Phase 2 | Deep | View | |||
| CheckMate 9LA NCT03215706 · Bristol-Myers Squibb DeepView → | first-line metastatic non-small cell lung cancer | Phase 3 | Deep | View | |||
| CheckMate 743 NCT02899299 · Bristol-Myers Squibb DeepView → | first-line unresectable malignant pleural mesothelioma | Phase 3 | Deep | View | |||
| RELATIVITY-047 NCT03470922 · Bristol-Myers Squibb DeepView → | previously untreated unresectable or metastatic melanoma | Phase 2/Phase 3 | Deep | View | |||
| CheckMate 901 NCT03036098 · Bristol-Myers Squibb DeepView → | previously untreated unresectable or metastatic urothelial carcinoma | Phase 3 | Deep | View | |||
| CheckMate 7FL NCT04109066 · Bristol-Myers Squibb DeepView → | high-risk ER+ HER2- primary breast cancer | Phase 3 | Deep | View | |||
| TRANSCEND CLL 004 NCT03331198 · Juno Therapeutics, a Subsidiary of Celgene DeepView → | relapsed/refractory CLL or SLL | Phase 1/Phase 2 | Deep | View | |||
| CheckMate 648 NCT03143153 · Bristol-Myers Squibb DeepView → | previously untreated advanced esophageal squamous cell carcinoma | Phase 3 | Deep | View | |||
| CheckMate 025 NCT01668784 · Bristol-Myers Squibb DeepView → | pre-treated advanced or metastatic clear-cell renal cell carcinoma | Phase 3 | Deep | View | |||
| ACTION-1 NCT05477576 · RayzeBio, Inc. DeepView → | SSTR+ well-differentiated GEP-NET with progression following 177Lu-SSA therapy | Phase 3 | Deep | View | |||
| TRANSCEND NHL 001 NCT02631044 · Juno Therapeutics, a Subsidiary of Celgene DeepView → | relapsed or refractory B-cell non-Hodgkin lymphoma | Phase 1 | Deep | View | |||
| CheckMate 238 NCT02388906 · Bristol-Myers Squibb DeepView → | resected stage IIIB–C or stage IV melanoma | Phase 3 | Deep | View | |||
| CheckMate 67T NCT04810078 · Bristol-Myers Squibb DeepView → | previously treated advanced clear cell renal cell carcinoma | Phase 3 | Deep | View | |||
| KRYSTAL-10 NCT04793958 · Mirati Therapeutics Inc. DeepView → | advanced colorectal cancer with KRAS G12C mutation | Phase 3 | Deep | View | |||
| APACT NCT01964430 · Celgene DeepView → | resected pancreatic ductal adenocarcinoma | Phase 3 | Deep | View | |||
| CheckMate 032 NCT01928394 · Bristol-Myers Squibb DeepView → | advanced or metastatic solid tumors | Phase 1/Phase 2 | Deep | View | |||
| TRANSCEND FL NCT04245839 · Celgene DeepView → | relapsed or refractory indolent B-cell non-Hodgkin lymphoma | Phase 2 | Deep | View | |||
| JAKARTA-2 NCT01523171 · Bristol-Myers Squibb DeepView → | myelofibrosis previously treated with ruxolitinib | Phase 2 | Deep | View | |||
| CheckMate 459 NCT02576509 · Bristol-Myers Squibb DeepView → | first-line advanced hepatocellular carcinoma | Phase 3 | Deep | View | |||
| SUCCESSOR-1 NCT05519085 · Celgene DeepView → | relapsed or refractory multiple myeloma | Phase 3 | Deep | View | |||
| CheckMate 816 NCT02998528 · Bristol-Myers Squibb DeepView → | resectable non-small-cell lung cancer | Phase 3 | Deep | View | |||
| KarMMa-2 NCT03601078 · Celgene DeepView → | relapsed/refractory or high-risk multiple myeloma | Phase 2 | Deep | View | |||
| CheckMate 722 NCT02864251 · Bristol-Myers Squibb DeepView → | EGFR-mutated metastatic non-small-cell lung cancer after TKI progression | Phase 3 | Deep | View | |||
| CheckMate 73L NCT04026412 · Bristol-Myers Squibb DeepView → | previously untreated, locally advanced stage III NSCLC | Phase 3 | Deep | View | |||
| FREEDOM2 NCT03952039 · Celgene DeepView → | myelofibrosis previously treated with ruxolitinib | Phase 3 | Deep | View | |||
| OPTIMISMM NCT01734928 · Celgene DeepView → | lenalidomide-pretreated relapsed or refractory multiple myeloma | Phase 3 | Deep | View | |||
| RELATIVITY-098 NCT05002569 · Bristol-Myers Squibb DeepView → | stage III/IV melanoma after complete resection | Phase 3 | Deep | View | |||
| CheckMate 057 NCT01673867 · Bristol-Myers Squibb DeepView → | previously treated metastatic non-squamous NSCLC | Phase 3 | Deep | View | |||
| QUAZAR AML-001 NCT01757535 · Celgene DeepView → | acute myeloid leukemia in first remission | Phase 3 | Deep | View | |||
| CheckMate 451 NCT02538666 · Bristol-Myers Squibb DeepView → | extensive-stage small cell lung cancer after chemotherapy | Phase 3 | Deep | View | |||
| CheckMate 744 NCT02927769 · Bristol-Myers Squibb DeepView → | relapsed/refractory CD30+ classic Hodgkin lymphoma | Phase 2 | Deep | View | |||
| CheckMate 915 NCT03068455 · Bristol-Myers Squibb DeepView → | resected stage IIIB-D or stage IV melanoma | Phase 3 | Deep | View | |||
| CheckMate 141 NCT02105636 · Bristol-Myers Squibb DeepView → | platinum-refractory recurrent/metastatic head and neck squamous cell carcinoma | Phase 3 | Deep | View | |||
| CheckMate 650 NCT02985957 · Bristol-Myers Squibb DeepView → | metastatic castration-resistant prostate cancer | Phase 2 | Deep | View | |||
| CheckMate 8HW NCT04008030 · Bristol-Myers Squibb DeepView → | MSI-H/dMMR metastatic colorectal cancer | Phase 3 | Deep | View | |||
| KRYSTAL-7 NCT04613596 · Mirati Therapeutics Inc. DeepView → | KRAS G12C-mutated advanced non-small cell lung cancer | Phase 2/Phase 3 | Deep | View | |||
| ELOQUENT-2 NCT01239797 · Bristol-Myers Squibb StandardView → | relapsed or refractory multiple myeloma | Phase 3 | Standard | View | |||
| CheckMate 9DX NCT03383458 · Bristol-Myers Squibb StandardView → | high-risk hepatocellular carcinoma after curative resection or ablation | Phase 3 | Standard | View | |||
| QUINTESSENTIAL-2 NCT06615479 · Juno Therapeutics, Inc., a Bristol-Myers Squibb Company StandardView → | lenalidomide-exposed relapsed or refractory multiple myeloma | Phase 3 | Standard | View | |||
| RELATIVITY-020 NCT01968109 · Bristol-Myers Squibb StandardView → | advanced solid tumors | Phase 1/Phase 2 | Standard | View | |||
| CheckMate 331 NCT02481830 · Bristol-Myers Squibb StandardView → | relapsed small-cell lung cancer | Phase 3 | Standard | View | |||
| CheckMate 205 NCT02181738 · Bristol-Myers Squibb StandardView → | classical Hodgkin lymphoma | Phase 2 | Standard | View | |||
| KarMMa-4 NCT04196491 · Celgene StandardView → | high-risk newly diagnosed multiple myeloma | Phase 1 | Standard | View | |||
| CheckMate 651 NCT02741570 · Bristol-Myers Squibb StandardView → | first-line recurrent/metastatic head and neck squamous cell carcinoma | Phase 3 | Standard | View | |||
| CheckMate 016 NCT01472081 · Bristol-Myers Squibb StandardView → | clear-cell metastatic renal cell carcinoma | Phase 1 | Standard | View | |||
| ACE-536-MF-001 NCT03194542 · Celgene StandardView → | myelofibrosis with anemia | Phase 2 | Standard | View | |||
| KRYSTAL-2 NCT04330664 · Mirati Therapeutics Inc. FocusedView → | advanced solid tumors with KRAS G12C mutation | Phase 1 | Focused | View | |||
| CC-95266-MM-001 NCT04674813 · Juno Therapeutics, a Subsidiary of Celgene FocusedView → | relapsed/refractory multiple myeloma | Phase 1 | Focused | View | |||
| CheckMate 7DX NCT04100018 · Bristol-Myers Squibb FocusedView → | chemotherapy-naive metastatic castration-resistant prostate cancer | Phase 3 | Focused | View | |||
| NCT03680521 NCT03680521 · Mirati Therapeutics Inc. FocusedView → | locally advanced clear cell renal cell carcinoma | Phase 2 | Focused | View | |||
| SAPPHIRE NCT03906071 · Mirati Therapeutics Inc. FocusedView → | Not given | Phase 3 | Focused | View | |||
| CC-92480-MM-002 NCT03989414 · Celgene FocusedView → | relapsed, refractory or newly diagnosed multiple myeloma | Phase 1/Phase 2 | Focused | View | |||
| RELATIVITY-1093 NCT06561386 · Bristol-Myers Squibb FocusedView → | Not given | Phase 3 | Focused | View | |||
| KRYSTAL-4 NCT06875310 · Mirati Therapeutics Inc. FocusedView → | untreated KRAS G12C non-squamous non-small cell lung cancer | Phase 3 | Focused | View | |||
| CheckMate 920 NCT02982954 · Bristol-Myers Squibb FocusedView → | previously untreated advanced renal cell carcinoma | Phase 4 | Focused | View | |||
| NCT03486067 NCT03486067 · Celgene FocusedView → | relapsed and refractory multiple myeloma | Phase 1 | Focused | View | |||
| COMMANDS NCT03682536 · Celgene FocusedView → | Not given | Phase 3 | Focused | View | |||
| NCT04209114 NCT04209114 · Bristol-Myers Squibb FocusedView → | cisplatin-ineligible muscle-invasive bladder cancer | Phase 3 | Focused | View | |||
| KarMMa-7 NCT04855136 · Celgene FocusedView → | Not given | Phase 1 | Focused | View | |||
| RELATIVITY-123 NCT05328908 · Bristol-Myers Squibb FocusedView → | later-line MSS metastatic colorectal cancer | Phase 3 | Focused | View | |||
| MEDALIST NCT02631070 · Celgene FocusedView → | transfusion-dependent lower-risk myelodysplastic syndromes with ring sideroblasts | Phase 3 | Focused | View | |||
| CheckMate 9UT NCT03519256 · Bristol-Myers Squibb FocusedView → | BCG-unresponsive high-risk non-muscle invasive bladder cancer | Phase 2 | Focused | View | |||
| TRANSFORM NCT03575351 · Celgene FocusedView → | Not given | Phase 3 | Focused | View | |||
| CA209-8Y8 NCT03873402 · Bristol-Myers Squibb FocusedView → | previously untreated intermediate/poor-risk advanced renal cell carcinoma | Phase 3 | Focused | View | |||
| CC-94676-PCA-001 NCT04428788 · Celgene FocusedView → | metastatic castration-resistant prostate cancer | Phase 1 | Focused | View | |||
| NCT05737706 NCT05737706 · Mirati Therapeutics Inc. FocusedView → | Not given | Phase 1 | Focused | View | |||
| MountainTAP-30 NCT07076121 · Bristol-Myers Squibb FocusedView → | Not given | Phase 2/Phase 3 | Focused | View | |||